Injectable collagen scaffold with human umbilical cordderived mesenchymal stem cells promotes functional recovery in patients with spontaneous intracerebral hemorrhage:phase Ⅰ clinical trial

作     者：Xiao-Yin Li Wu-Sheng Deng Zi-Qi Wang Zheng-Chao Li Shu-Lian Chen Zhen Song Quan Zhang Jin Liang Xu-Yi Chen Xiao-Yin Li;Wu-Sheng Deng;Zi-Qi Wang;Zheng-Chao Li;Shu-Lian Chen;Zhen Song;Quan Zhang;Jin Liang;Xu-Yi Chen

作者机构：Characteristic Medical Center of Chinese People’s Armed Police ForceTianjin Key Laboratory of Neurotrauma RepairTianjinChina Department of NeurosurgeryDazhou Second People’s HospitalDazhouSichuan ProvinceChina Graduate School of Tianjin University of Traditional Chinese MedicineTianjinChina 

出 版 物：《Neural Regeneration Research》 (中国神经再生研究（英文版）)

年 卷 期：2023年第18卷第9期

页      面：1999-2004页

核心收录：

学科分类：0710[理学-生物学] 1002[医学-临床医学] 1001[医学-基础医学(可授医学、理学学位)] 100204[医学-神经病学] 10[医学] 

基　　金：supported by the National Key Research and Development Plan of China,No.2016YFC1101500 (to ZS) the National Natural Science Foundation of China,Nos.11932013 and 11672332 (both to XYC)。 

主　　题：clinical trial collagen scaffold efficacy human umbilical cord-derived mesenchymal stem cells human safe neurological recovery spontaneous intracerebral hemorrhage transplantation 

摘      要：Animal expe riments have shown that injectable collagen scaffold with human umbilical cord-derived mesenchymal stem cells can promote recovery from spinal cord injury.To investigate whether injectable collagen scaffold with human umbilical cord-derived mesenchymal stem cells can be used to treat spontaneous intracerebral hemorrhage,this non-randomized phase I clinical trial recruited patients who met the inclusion criteria and did not meet the exclusion crite ria of spontaneous intracerebral hemorrhage treated in the Characteristic Medical Center of Chinese People’s Armed Police Force from May 2016 to December 2020.Patients were divided into three groups according to the clinical situation and patient benefit:control(n=18),human umbilical cord-derived mesenchymal stem cells(n=4),and combination(n=8).The control group did not receive any transplantation.The human umbilical cord-derived mesenchymal stem cells group received human umbilical cord-derived mesenchymal stem cell transplantation.The combination group received injectable collagen scaffold with human umbilical cord-derived mesenchymal stem cells.Patients who received injectable collagen scaffold with human umbilical cord-derived mesenchymal stem cells had more remarkable improvements in activities of daily living and cognitive function and smaller foci of intra cerebral hemorrhage-related encephalomalacia.Severe adve rse events associated with cell transplantation were not observed.Injectable collagen scaffold with human umbilical cord-derived mesenchymal stem cells appears to have great potential treating spontaneous intracerebral hemorrhage.